Click through the slideshow to find concise summaries of conference highlights.
1 in 12 Lupus Neprhitis Patients Experience Cardiovascular Events
Emerging Agents in the Treatment of Rheumatic Diseases
FDA Approves Voclosporin Label Update in Lupus Nephritis to Reflect Long-Term Data
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg
MRI Treat-to-Target Strategy Fails to Help RA Patients Reach Remission